Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

Background: Therapeutic options for CD19(+) relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed. Here, we explore the immunophenotyping and lysis sensitivity of CD19(+) ALL relapse after anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Grain, Audrey, Ollier, Jocelyn, Guillaume, Thierry, Chevallier, Patrice, Le Calvez, Baptiste, Eveillard, Marion, Clémenceau, Béatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953531/
https://www.ncbi.nlm.nih.gov/pubmed/36830882
http://dx.doi.org/10.3390/biomedicines11020345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953531/
https://www.ncbi.nlm.nih.gov/pubmed/36830882
http://dx.doi.org/10.3390/biomedicines11020345

Ejemplares similares